Organon Reports Mixed Q1 Results Amidst Pending Acquisition, Withdraws Guidance

summarizeSummary

Organon reported a 4% revenue decline and 30% adjusted EPS drop for Q1 2026, but GAAP EPS increased, with no future guidance provided due to its pending acquisition by Sun Pharma.

check_boxKey Events

• Q1 Revenue Decline

  Reported Q1 2026 revenue of $1.460 billion, a 4% decrease as-reported and 9% excluding foreign currency impact compared to Q1 2025.

• Mixed Profitability

  GAAP diluted EPS increased 67% to $0.55, while non-GAAP Adjusted diluted EPS decreased 30% to $0.71. Adjusted EBITDA also declined 14%.

• Biosimilars Segment Growth

  Biosimilars revenue increased 23% as-reported and 21% ex-FX, driven by strong performance of Hadlima and contributions from new assets.

• Guidance Withdrawn Due to Merger

  In light of the pending merger with Sun Pharmaceutical Industries, Organon will not provide future financial guidance or host quarterly earnings calls.

auto_awesomeAnalysis

Organon & Co. reported mixed financial results for the first quarter of 2026, with a 4% decline in as-reported revenue and a 30% drop in non-GAAP Adjusted diluted EPS. However, GAAP diluted EPS saw a significant 67% increase. The Biosimilars segment showed strong growth, up 23% as-reported, driven by Hadlima and new product contributions, which partially offset declines in Women's Health and Established Brands. The company has ceased providing financial guidance and will not host earnings calls due to its pending acquisition by Sun Pharmaceutical Industries, which was announced on April 26, 2026. This report provides a final detailed operational snapshot of the company's performance leading into the acquisition.